Genoscience Pharma (France)

Genoscience Pharma (France)

Open Access statistics for Genoscience Pharma (France), France, covering academic research published from 2002 to 2024.

Open Access statistics for Genoscience Pharma (France), France, covering academic research published from 2002 to 2024. Read More.


Open Access Percentage

61%


Total
Publications

57


Total Open
Publications

35


Total
Citations

665


Open Access
Percentage

61%


Total
Publications

57


Total Open
Publications

35


Total
Citations

665

Website

download

Breakdown

30% 28% 3% 39%

Publisher Open

30%

Both

28%

Other Platform Open

3%

Closed

39%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

00.511.522.533.544.555.566.57Total Publications
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

37%OA Journal

OA Journal 37%

12

Hybrid 30%

10

No Guarantees 33%

11

Other Platform Open

Domain 67%

12

Institution 44%

8

Other Internet 28%

5

Preprint 22%

4

Public 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
13
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
5
Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes
Institution
4
Le Centre pour la Communication Scientifique Directe - HAL - TYPE ART
Other Internet
4
bioRxiv
Preprint
4
University of Edinburgh - Edinburgh Research Explorer
Institution
2
Le Centre pour la Communication Scientifique Directe - HAL - IRD - Institut de Recherche pour le Développement
Institution
2
Le Centre pour la Communication Scientifique Directe - HAL - Aix-Marseille Université
Institution
2
DOI
Other Internet
2
Université Libre de Bruxelles - Dépôt institutionnel de l'Université libre de Bruxelles
Institution
1
1 / 2

Data updated 7 April 2025

Share

Share

Share